Skip to main content

Table 2 Univariate Analysis: Outcomes of patients with ACC based on prognostic factors

From: Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma

Overall survival a N HR* 95% CI p-value
Myb Staining (high vs. low) 63 1.05 0.45–2.44 0.9
Myb staining (present vs. absent) 63 1.57 0.63–3.8 0.4
Myb % tumor average (continuous) 64 0.99 0.98–1.01 0.6
Myb % tumor average (high vs. low) 64 1.05 0.45–2.44 0.9
ß-catenin cytoplasmic staining 62 2.45 0.9–6.7 0.08
Age at diagnosis 64 1.03 1.0–1.1 0.03
Race 63 0.92 0.5–1.9 0.8
Sex 64 1.06 0.4–2.6 0.8
Smoking history 57 2.9 1.1–8.2 0.03
Stage at diagnosis 56 2.21 1.2–4.2 0.02
Margin status 51 1.62 0.21–12.5 0.6
Dominant pattern 56 1.64 0.6–4.4 0.3
Treatment 64 1.31 0.6–3.1 0.5
Metastasisb   HR* 95% CI p-value
Myb Staining (high vs. low) 58 2.40 0.62–9.36 0.17
Myb staining (present vs. absent) 58 4.06 1.02–14.96 0.03
Myb % tumor average (continuous) 59 0.98 0.96–1.01 0.2
Myb % tumor average (high vs. low) 59 2.27 0.58–8.90 0.2
ß-cat cytoplasmic staining 57 1.35 0.39–4.67 0.64
Age at diagnosis 59 1.01 0.97–1.06 0.52
Race 58 0.36 0.08–1.57 0.18
Sex 59 0.46 0.09–2.22 0.34
Smoking history 54 0.72 0.15–3.59 0.69
Stage at diagnosis 51 1.62 0.79–3.32 0.19
Margin status 46
Dominant pattern 51
Treatment 59 1.22 0.34–4.37 0.76
Recurrencec   HR* 95% CI p-value
Myb Staining (high vs. low) a 58 1.61 0.61–4.25 0.33
Myb staining (present vs. absent) b 58 1.05 0.36–3.05 0.91
Myb % tumor average (continuous) 59 1.01 0.19–1.02 0.23
Myb % tumor average (high vs. low) 59 0.50 0.18–1.36 0.16
ß-cat cytoplasmic staining c 57 1.88 0.64–5.54 0.25
Age at diagnosis 59 1.03 0.99–1.07 0.13
Race 58 1.22 0.55–2.74 0.62
Sex 59 0.43 0.14–1.35 0.15
Smoking history 54 1.99 0.67–5.95 0.22
Stage at diagnosis 51 3.31 1.02–10.69 0.04
Margin status 46
Dominant pattern 51 1.56 0.32,7.54 0.58
Treatment 59 1.08 0.33–3.54 0.89
  1. The N in the table is presented as a separate column because each predictor had a differential amount of missing, and thus the sample size is not consistent among models fit to assess the different associations.
  2. *: Hazard Ratios
  3. ** Follow-up information regarding overall survival, metastasis, and recurrence was missing for 9 patients, 11 patients, and 12 patients, respectively. Additionally, ß-cat staining information was unavailable for 2 patients, and Myb staining information was unavailable for 1 patient.
  4. No estimates have been presented for margin status and dominant histologic pattern. All cases of recurrence and metastasis had a positive margin status. Given the small sample size and missing patient information for dominant histologic pattern, a survival model could not be fit to accurately analyze the data to provide conclusive results.
  5. aThe average follow-up time for patients in whom overall survival was evaluated was 58.3 months, ranging from 0 to 303.1 months
  6. bThe average follow-up time for patients in whom metastasis was evaluated was 51.5 months, ranging from 0 to 262.5 months
  7. cThe average follow-up time for patients in whom overall recurrence was evaluated was 50 months, ranging from 0.07–244.5 months